In the 8th Turkish Pharmaceutical Market Monitoring Report, published by the Turkish Medicines and Medical Devices Agency (TİTCK) of the Ministry of Health, the sales volumes and sales values of the drugs in the Turkish market in 2020 on the basis of boxes and TL were examined.
In addition, data on drugs sold in pharmacies, covered by the Social Security Institution (SGK) and private insurances, and ranked in the top 20 in sales volume, were also reflected in the report.
According to the report prepared by using Quintiles and IMS Health (IQVIA) and Drug Tracking System (ITS) databases, the Turkish pharmaceutical market, which was 18.08 billion liras in 2015, reached a sales value of 50.39 billion liras in 2020.
It was observed that the sales volume, which was 2.1 billion boxes in 2015, increased to 2.27 billion boxes in 2020, but this rate decreased compared to 2019. In 2019, a sales volume of 2.41 billion boxes was achieved in Turkey.
Top 20 best-selling drugs
Painkillers and drugs used in the treatment of rheumatism took the first three places among the first 20 drugs sold in total and by hand and covered by SGK and private insurances throughout Turkey in the previous year.
While the ratio of drugs with painkiller properties reached 35 percent, those used in the treatment of rheumatism and anti-inflammatory drugs followed with 30.2 percent. In the third place, “antithrombotic” drugs that prevent blood clotting took place.
Among the drugs covered by the SSI, general nutritional drugs (21.6 percent), drugs that prevent blood clotting (17.7 percent) and painkillers (14.3 percent) took the first three places.
Among the drugs covered by private insurance, those used in anti-inflammatory and rheumatism treatments ranked first with 14.7 percent, antibacterials used systemically took the second place with 11.6 percent, and antithrombotic drugs were in the third place.
The amount paid by SSI for the first 20 drugs exceeded 2 billion liras.
According to the report, 76.57 percent of the drugs sold in Turkey in 2020 were covered by SGK, 1.1 percent by private insurance, and 22.32 percent by hand.
The amount paid by SGK to the first 20 drugs with the highest total box sales in 2020 was 2 billion 201 million 766 thousand 772 liras. While the total cost of drugs sold by hand reached 857 million 223 thousand 198 liras, the cost of drugs covered by private insurance was reflected in the report as 29 million 793 thousand 175 liras.
Sales value of biotech drugs doubled
In the report, the market situations of biotechnological drugs, which are considered as strategic products by the Ministry of Health and which are one of the main topics of investment incentives, were examined in a way to cover the years 2015 and 2020.
Accordingly, biotechnological drugs, which showed a sales value of 3.05 billion liras in 2015, doubled to 8.85 billion liras in 2020. In 2020, the share of the biotechnological pharmaceutical market in the total pharmaceutical market was 17.6%.
When evaluated in terms of sales value in 2020, the manufacturing market increased by 54 percent in 2020 compared to 2019. The sales volumes of licensed biotechnological products, which are in the top 20 in terms of sales volume, covered by SGK and private insurances, were 23 million 558 thousand 859 boxes and 150 thousand 686 boxes, respectively. Hand sales volume was 1 million 278 thousand 195 boxes.
63.7 percent of these products were “drugs used in the treatment of diabetes”.
On the other hand, antithrombotic drugs took the first 5 places among the top 20 biosimilar drugs according to 2020 sales volumes with a rate of 89.3 percent.